View ValuationSoftOx Solutions 将来の成長Future 基準チェック /06現在、 SoftOx Solutionsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長10.7%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updates分析記事 • Mar 28We Think SoftOx Solutions (OB:SOFTX) Needs To Drive Business Growth CarefullyEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...New Risk • Mar 26New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr19m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr19m free cash flow). Share price has been highly volatile over the past 3 months (21% average weekly change). Minor Risks Revenue is less than US$5m (kr16m revenue, or US$1.6m). Market cap is less than US$100m (kr174.4m market cap, or US$18.1m).New Risk • Dec 29New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Norwegian stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (16% average weekly change). Minor Risks Shareholders have been diluted in the past year (23% increase in shares outstanding). Revenue is less than US$5m (kr14m revenue, or US$1.4m). Market cap is less than US$100m (kr219.9m market cap, or US$21.9m).お知らせ • Dec 19+ 5 more updatesSoftOx Solutions AS, Annual General Meeting, Jun 23, 2027SoftOx Solutions AS, Annual General Meeting, Jun 23, 2027.お知らせ • Sep 27SoftOx Solutions AS announced that it has received NOK 6 million in funding from Long State Investments LimitedOn September 26, 2025, SoftOx Solutions AS closed the transaction.お知らせ • Jun 30SoftOx Solutions AS Appoints Tore Duvold as New Board MemberSoftOx Solutions AS at its Annual General Meeting, announced the election of Dr. Tore Duvold as a new member of the Board of Directors. Dr. Duvold brings over 25 years of experience in the life science sector, including leadership roles in biotech, pharma, and public innovation funding. He currently serves as CEO of the Swedish diagnostics company Spermosens AB and has held senior positions at LEO Pharma, Aker Biopharma AS, Innovation Fund Denmark, Edvince AB, and Coegin Pharma. In addition, he has served on the board of Medicon Valley Alliance and been involved in several board roles.お知らせ • May 27+ 1 more updateSoftOx Solutions AS to Report Fiscal Year 2025 Results on May 27, 2026SoftOx Solutions AS announced that they will report fiscal year 2025 results on May 27, 2026お知らせ • Dec 19SoftOx Solutions AS, Annual General Meeting, Jun 24, 2026SoftOx Solutions AS, Annual General Meeting, Jun 24, 2026.お知らせ • Dec 18+ 4 more updatesSoftOx Solutions AS to Report Fiscal Year 2025 Results on Jun 10, 2026SoftOx Solutions AS announced that they will report fiscal year 2025 results on Jun 10, 2026お知らせ • Sep 13SoftOx Solutions AS to Appeal Court Ruling in Consultant Bonus DisputeThe District Court of Ringerike, Asker, and Bærum has made its ruling in a dispute between SoftOx Solutions AS and a former consultant claiming to have a bonus claim for services rendered in 2022. The district court ruled in favor of the consultant and awarded the consultant approx. NOK 2.5 million plus interest, and NOK 484,000 in compensation including legal costs. The Company believes that the claim has no merits, and the ruling will be appealed.お知らせ • Sep 12SoftOx Solutions AS Elects Additional Board MembersSoftOx Solutions AS at its ExtraOrdinary General Meeting held on 12 September 2024, elected as additional board member: Christian Vinding Thomsen, Vice Chairman of the Board and Eskil Zapffe, board member with an election term until the annual general meeting in 2025.お知らせ • Jul 03+ 1 more updateSoftox Solutions as Announces CFO ChangesSoftOx Solutions AS announced that in this process the former CFO Harald Sætvedt has stepped down and will be replaced by CFO Ingrid Juven. Ingrid Juven has over 25+ years of consulting and management expertise within a variety of industries. Juven holds an MBA from BI Norwegian Business School.お知らせ • May 01SoftOx Solutions AS has completed a Follow-on Equity Offering in the amount of NOK 2.66919 million.SoftOx Solutions AS has completed a Follow-on Equity Offering in the amount of NOK 2.66919 million. Security Name: Shares Security Type: Common Stock Securities Offered: 13,345,951 Price\Range: NOK 0.2 Transaction Features: Rights OfferingNew Risk • Apr 11New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Over 47x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (29% average weekly change). Earnings have declined by 21% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 47x increase in shares outstanding). Revenue is less than US$1m (kr7.0m revenue, or US$645k). Minor Risks Negative equity (-kr268k). Market cap is less than US$100m (kr156.1m market cap, or US$14.4m).New Risk • Apr 05New minor risk - Negative shareholders equityThe company has negative equity. Total equity: -kr268k This is considered a minor risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. It should be noted that some of the negative equity could be due to large buybacks of stock, which is not as much of a risk as a company with overwhelming debt, but likewise is not sustainable in the long-term. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (29% average weekly change). Earnings have declined by 21% per year over the past 5 years. Revenue is less than US$1m (kr7.0m revenue, or US$650k). Market cap is less than US$10m (kr4.29m market cap, or US$399.5k). Minor Risks Negative equity (-kr268k). Shareholders have been diluted in the past year (3.7% increase in shares outstanding).お知らせ • Mar 28SoftOx Solutions AS has filed a Follow-on Equity Offering in the amount of NOK 25 million.SoftOx Solutions AS has filed a Follow-on Equity Offering in the amount of NOK 25 million. Security Name: Shares Security Type: Common Stock Securities Offered: 125,000,000 Price\Range: NOK 0.2 Transaction Features: Rights OfferingNew Risk • Mar 27New major risk - Revenue sizeThe company makes less than US$1m in revenue. Total revenue: kr7.0m (US$649k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (26% average weekly change). Earnings have declined by 21% per year over the past 5 years. Revenue is less than US$1m (kr7.0m revenue, or US$649k). Market cap is less than US$10m (kr8.84m market cap, or US$821.8k). Minor Risks Negative equity (-kr268k). Shareholders have been diluted in the past year (3.7% increase in shares outstanding).お知らせ • Jan 25+ 5 more updatesSoftOx Solutions AS to Report Fiscal Year 2024 Final Results on Jun 18, 2025SoftOx Solutions AS announced that they will report fiscal year 2024 final results on Jun 18, 2025New Risk • Sep 27New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr41m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr41m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 33% per year over the past 5 years. Market cap is less than US$10m (kr51.7m market cap, or US$4.79m). Minor Risk Revenue is less than US$5m (kr15m revenue, or US$1.4m).Board Change • Mar 10Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non-Executive Director Kari Myren was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Dec 30+ 4 more updatesSoftOx Solutions AS, Annual General Meeting, Mar 28, 2024SoftOx Solutions AS, Annual General Meeting, Mar 28, 2024.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Chairman Melvin Teigen was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.分析記事 • Sep 01Is SoftOx Solutions (OB:SOFTX) In A Good Position To Deliver On Growth Plans?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...お知らせ • Mar 17Danish Medicines Agency Approves First-In-Human Clinical Study for SoftOx Solutions AS Wound Treatment Agent for Infections in Chronic Wounds, Biofilm EradicatorSoftOx Solutions AS announced that the Danish Medicines Agency (DKMA) has authorised the SBE-01 clinical trial on medicinal products. The authorisation is given pursuant to § 88(1) of the Danish Medicines Act.1. This is the first-in-man (phase I) study with lead wound care product, SBE, designed to treat infected chronic wounds. The study will establish a tolerable dose and treatment schedule for SBE to be able to develop it into an effective infection-treatment solution in problematic, non-healing wounds. This approval represents an important milestone for SoftOx Solutions AS and is of crucial importance for the further development of an effective infection treatment of problematic wounds, where there is an unmet medical need. It is also an important step forward for the company's collaboration and funding partners, such as University of Copenhagen, Bispebjerg University Hospital, US Naval Medical Research Center (NMRC) under Medical Technology Enterprise Consortium (MTEC) and The Research Council of Norway. The SBE-01 study will commence as soon as permission has also been granted by the relevant Scientific Ethical Committee. SBE-01: EudraCT no. 2021-000314-42.Is New 90 Day High Low • Feb 20New 90-day low: kr56.50The company is down 18% from its price of kr68.50 on 20 November 2020. The Norwegian market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 2.0% over the same period.分析記事 • Feb 19How Many SoftOx Solutions AS (OB:SOFTX) Shares Have Insiders Sold, In The Last Year?We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...分析記事 • Jan 15SoftOx Solutions (OB:SOFTX) Will Have To Spend Its Cash WiselyJust because a business does not make any money, does not mean that the stock will go down. Indeed, SoftOx Solutions...お知らせ • Dec 23SoftOx Solutions AS Announces New Distribution AgreementSoftOx Solutions AS announced new distribution agreement. Distributor Bonaventura Scandza has signed an agreement with NorgesGruppen for the sale of SafeDes alcohol-free hand disinfectant. From February, some of the country's grocery chains will start selling SoftOx SafeDes hand disinfectant under the brand name «Aeris». The agreement with NorgesGruppen includes Meny, Spar, and Bunnpris stores, where 39 Meny stores will include the products in a fixed listing, while partner Bonaventura Scandza will be allowed to sell products to all the other stores locally. Meny has a total of 200 stores, Spar has 295, and Bunnpris has 250. As a result of increased focus on infection prevention and control among consumers, Bonaventura Scandza in collaboration with Aeris AS and SoftOx Solutions AS has created a new category for infection control products under the Aeris brand, which includes hand disinfectants from SoftOx Solutions. These three companies will now together market and sell Aeris's products to the pharmacies and the retail market in the Nordic countries and the UK.お知らせ • Dec 18+ 1 more updateUniversity of Copenhagen and SoftOx Solutions Reports on Positive Results on SoftOx Inhalation SolutionUniversity of Copenhagen and SoftOx Solutions reports on positive results on SoftOx Inhalation Solution (SIS). SoftOx Inhalation Solution (SIS) is an inhalation solution where the hypothesis is that it should be able to treat all types of respiratory tract infections. This could potentially be a paradigm shift in the treatment of all types of respiratory infections.お知らせ • Dec 13+ 4 more updatesSoftOx Solutions AS to Report Q4, 2020 Results on Mar 31, 2021SoftOx Solutions AS announced that they will report Q4, 2020 results on Mar 31, 2021Is New 90 Day High Low • Sep 28New 90-day high: kr81.00The company is up 9.0% from its price of kr74.50 on 30 June 2020. The Norwegian market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 2.0% over the same period.お知らせ • Sep 26+ 1 more updateSoftOx Solutions AS Receives the Results of the Inhalation Studies in MinipigsSoftOx Solutions AS received the results of the inhalation studies in minipigs, which show very promising results with the intention to further develop the company's technology into a treatment of respiratory infections, including Covid19 patients. The results indicate that the company has found safe concentrations that do not damage the airways and at the same time show an antimicrobial effect. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、SoftOx Solutions は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OB:SOFTX - アナリストの将来予測と過去の財務データ ( )NOK Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202516-11-19-19N/A9/30/202514-3-152N/A6/30/202511-15-33-16N/A3/31/20259-201332N/A12/31/20248-431333N/A9/30/20242-73712N/A6/30/20242-612734N/A3/31/2024-1-58-16-7N/A12/31/20237-39-71N/A9/30/202314-17-35-28N/A6/30/202315-34-41-35N/A3/31/202316-50-65-61N/A12/31/20227-71-91-86N/A9/30/20227-68-71-65N/A6/30/20226-66-81-76N/A3/31/20227-67-78-73N/A12/31/20218-65-77-73N/A9/30/20216-74-76-73N/A6/30/20216-64-71-70N/A3/31/202110-53-67-61N/A12/31/202010-37-68-60N/A9/30/20209-30-49-38N/A6/30/20209-24-41-30N/A3/31/20204-19-29-25N/A12/31/20194-16-14-11N/A9/30/20195-17N/A-17N/A6/30/20197-13N/A-18N/A3/31/20196-13N/A-15N/A12/31/20184-13N/A-15N/A9/30/20183-10N/A-19N/A6/30/2018N/A-12N/A-19N/A3/31/20180-11N/A-18N/A12/31/20170-9N/A-15N/A12/31/20160-6N/AN/AN/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: SOFTXの予測収益成長が 貯蓄率 ( 3.3% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: SOFTXの収益がNorwegian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: SOFTXの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: SOFTXの収益がNorwegian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: SOFTXの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: SOFTXの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/26 15:16終値2026/05/22 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋SoftOx Solutions AS 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
分析記事 • Mar 28We Think SoftOx Solutions (OB:SOFTX) Needs To Drive Business Growth CarefullyEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
New Risk • Mar 26New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr19m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr19m free cash flow). Share price has been highly volatile over the past 3 months (21% average weekly change). Minor Risks Revenue is less than US$5m (kr16m revenue, or US$1.6m). Market cap is less than US$100m (kr174.4m market cap, or US$18.1m).
New Risk • Dec 29New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Norwegian stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (16% average weekly change). Minor Risks Shareholders have been diluted in the past year (23% increase in shares outstanding). Revenue is less than US$5m (kr14m revenue, or US$1.4m). Market cap is less than US$100m (kr219.9m market cap, or US$21.9m).
お知らせ • Dec 19+ 5 more updatesSoftOx Solutions AS, Annual General Meeting, Jun 23, 2027SoftOx Solutions AS, Annual General Meeting, Jun 23, 2027.
お知らせ • Sep 27SoftOx Solutions AS announced that it has received NOK 6 million in funding from Long State Investments LimitedOn September 26, 2025, SoftOx Solutions AS closed the transaction.
お知らせ • Jun 30SoftOx Solutions AS Appoints Tore Duvold as New Board MemberSoftOx Solutions AS at its Annual General Meeting, announced the election of Dr. Tore Duvold as a new member of the Board of Directors. Dr. Duvold brings over 25 years of experience in the life science sector, including leadership roles in biotech, pharma, and public innovation funding. He currently serves as CEO of the Swedish diagnostics company Spermosens AB and has held senior positions at LEO Pharma, Aker Biopharma AS, Innovation Fund Denmark, Edvince AB, and Coegin Pharma. In addition, he has served on the board of Medicon Valley Alliance and been involved in several board roles.
お知らせ • May 27+ 1 more updateSoftOx Solutions AS to Report Fiscal Year 2025 Results on May 27, 2026SoftOx Solutions AS announced that they will report fiscal year 2025 results on May 27, 2026
お知らせ • Dec 19SoftOx Solutions AS, Annual General Meeting, Jun 24, 2026SoftOx Solutions AS, Annual General Meeting, Jun 24, 2026.
お知らせ • Dec 18+ 4 more updatesSoftOx Solutions AS to Report Fiscal Year 2025 Results on Jun 10, 2026SoftOx Solutions AS announced that they will report fiscal year 2025 results on Jun 10, 2026
お知らせ • Sep 13SoftOx Solutions AS to Appeal Court Ruling in Consultant Bonus DisputeThe District Court of Ringerike, Asker, and Bærum has made its ruling in a dispute between SoftOx Solutions AS and a former consultant claiming to have a bonus claim for services rendered in 2022. The district court ruled in favor of the consultant and awarded the consultant approx. NOK 2.5 million plus interest, and NOK 484,000 in compensation including legal costs. The Company believes that the claim has no merits, and the ruling will be appealed.
お知らせ • Sep 12SoftOx Solutions AS Elects Additional Board MembersSoftOx Solutions AS at its ExtraOrdinary General Meeting held on 12 September 2024, elected as additional board member: Christian Vinding Thomsen, Vice Chairman of the Board and Eskil Zapffe, board member with an election term until the annual general meeting in 2025.
お知らせ • Jul 03+ 1 more updateSoftox Solutions as Announces CFO ChangesSoftOx Solutions AS announced that in this process the former CFO Harald Sætvedt has stepped down and will be replaced by CFO Ingrid Juven. Ingrid Juven has over 25+ years of consulting and management expertise within a variety of industries. Juven holds an MBA from BI Norwegian Business School.
お知らせ • May 01SoftOx Solutions AS has completed a Follow-on Equity Offering in the amount of NOK 2.66919 million.SoftOx Solutions AS has completed a Follow-on Equity Offering in the amount of NOK 2.66919 million. Security Name: Shares Security Type: Common Stock Securities Offered: 13,345,951 Price\Range: NOK 0.2 Transaction Features: Rights Offering
New Risk • Apr 11New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Over 47x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (29% average weekly change). Earnings have declined by 21% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 47x increase in shares outstanding). Revenue is less than US$1m (kr7.0m revenue, or US$645k). Minor Risks Negative equity (-kr268k). Market cap is less than US$100m (kr156.1m market cap, or US$14.4m).
New Risk • Apr 05New minor risk - Negative shareholders equityThe company has negative equity. Total equity: -kr268k This is considered a minor risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. It should be noted that some of the negative equity could be due to large buybacks of stock, which is not as much of a risk as a company with overwhelming debt, but likewise is not sustainable in the long-term. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (29% average weekly change). Earnings have declined by 21% per year over the past 5 years. Revenue is less than US$1m (kr7.0m revenue, or US$650k). Market cap is less than US$10m (kr4.29m market cap, or US$399.5k). Minor Risks Negative equity (-kr268k). Shareholders have been diluted in the past year (3.7% increase in shares outstanding).
お知らせ • Mar 28SoftOx Solutions AS has filed a Follow-on Equity Offering in the amount of NOK 25 million.SoftOx Solutions AS has filed a Follow-on Equity Offering in the amount of NOK 25 million. Security Name: Shares Security Type: Common Stock Securities Offered: 125,000,000 Price\Range: NOK 0.2 Transaction Features: Rights Offering
New Risk • Mar 27New major risk - Revenue sizeThe company makes less than US$1m in revenue. Total revenue: kr7.0m (US$649k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (26% average weekly change). Earnings have declined by 21% per year over the past 5 years. Revenue is less than US$1m (kr7.0m revenue, or US$649k). Market cap is less than US$10m (kr8.84m market cap, or US$821.8k). Minor Risks Negative equity (-kr268k). Shareholders have been diluted in the past year (3.7% increase in shares outstanding).
お知らせ • Jan 25+ 5 more updatesSoftOx Solutions AS to Report Fiscal Year 2024 Final Results on Jun 18, 2025SoftOx Solutions AS announced that they will report fiscal year 2024 final results on Jun 18, 2025
New Risk • Sep 27New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr41m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr41m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 33% per year over the past 5 years. Market cap is less than US$10m (kr51.7m market cap, or US$4.79m). Minor Risk Revenue is less than US$5m (kr15m revenue, or US$1.4m).
Board Change • Mar 10Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non-Executive Director Kari Myren was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Dec 30+ 4 more updatesSoftOx Solutions AS, Annual General Meeting, Mar 28, 2024SoftOx Solutions AS, Annual General Meeting, Mar 28, 2024.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Chairman Melvin Teigen was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
分析記事 • Sep 01Is SoftOx Solutions (OB:SOFTX) In A Good Position To Deliver On Growth Plans?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
お知らせ • Mar 17Danish Medicines Agency Approves First-In-Human Clinical Study for SoftOx Solutions AS Wound Treatment Agent for Infections in Chronic Wounds, Biofilm EradicatorSoftOx Solutions AS announced that the Danish Medicines Agency (DKMA) has authorised the SBE-01 clinical trial on medicinal products. The authorisation is given pursuant to § 88(1) of the Danish Medicines Act.1. This is the first-in-man (phase I) study with lead wound care product, SBE, designed to treat infected chronic wounds. The study will establish a tolerable dose and treatment schedule for SBE to be able to develop it into an effective infection-treatment solution in problematic, non-healing wounds. This approval represents an important milestone for SoftOx Solutions AS and is of crucial importance for the further development of an effective infection treatment of problematic wounds, where there is an unmet medical need. It is also an important step forward for the company's collaboration and funding partners, such as University of Copenhagen, Bispebjerg University Hospital, US Naval Medical Research Center (NMRC) under Medical Technology Enterprise Consortium (MTEC) and The Research Council of Norway. The SBE-01 study will commence as soon as permission has also been granted by the relevant Scientific Ethical Committee. SBE-01: EudraCT no. 2021-000314-42.
Is New 90 Day High Low • Feb 20New 90-day low: kr56.50The company is down 18% from its price of kr68.50 on 20 November 2020. The Norwegian market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 2.0% over the same period.
分析記事 • Feb 19How Many SoftOx Solutions AS (OB:SOFTX) Shares Have Insiders Sold, In The Last Year?We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...
分析記事 • Jan 15SoftOx Solutions (OB:SOFTX) Will Have To Spend Its Cash WiselyJust because a business does not make any money, does not mean that the stock will go down. Indeed, SoftOx Solutions...
お知らせ • Dec 23SoftOx Solutions AS Announces New Distribution AgreementSoftOx Solutions AS announced new distribution agreement. Distributor Bonaventura Scandza has signed an agreement with NorgesGruppen for the sale of SafeDes alcohol-free hand disinfectant. From February, some of the country's grocery chains will start selling SoftOx SafeDes hand disinfectant under the brand name «Aeris». The agreement with NorgesGruppen includes Meny, Spar, and Bunnpris stores, where 39 Meny stores will include the products in a fixed listing, while partner Bonaventura Scandza will be allowed to sell products to all the other stores locally. Meny has a total of 200 stores, Spar has 295, and Bunnpris has 250. As a result of increased focus on infection prevention and control among consumers, Bonaventura Scandza in collaboration with Aeris AS and SoftOx Solutions AS has created a new category for infection control products under the Aeris brand, which includes hand disinfectants from SoftOx Solutions. These three companies will now together market and sell Aeris's products to the pharmacies and the retail market in the Nordic countries and the UK.
お知らせ • Dec 18+ 1 more updateUniversity of Copenhagen and SoftOx Solutions Reports on Positive Results on SoftOx Inhalation SolutionUniversity of Copenhagen and SoftOx Solutions reports on positive results on SoftOx Inhalation Solution (SIS). SoftOx Inhalation Solution (SIS) is an inhalation solution where the hypothesis is that it should be able to treat all types of respiratory tract infections. This could potentially be a paradigm shift in the treatment of all types of respiratory infections.
お知らせ • Dec 13+ 4 more updatesSoftOx Solutions AS to Report Q4, 2020 Results on Mar 31, 2021SoftOx Solutions AS announced that they will report Q4, 2020 results on Mar 31, 2021
Is New 90 Day High Low • Sep 28New 90-day high: kr81.00The company is up 9.0% from its price of kr74.50 on 30 June 2020. The Norwegian market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 2.0% over the same period.
お知らせ • Sep 26+ 1 more updateSoftOx Solutions AS Receives the Results of the Inhalation Studies in MinipigsSoftOx Solutions AS received the results of the inhalation studies in minipigs, which show very promising results with the intention to further develop the company's technology into a treatment of respiratory infections, including Covid19 patients. The results indicate that the company has found safe concentrations that do not damage the airways and at the same time show an antimicrobial effect.